Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib
Year: 2026
Type: article
Study design: Observational Study
Abstract: Aim: To assess real-world clinical outcomes in patients with non-small-cell lung cancerwith MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practice. Materials & methods: Patient data were collected using a retrospective medical record review, led by participating oncologists. Eligible patients initiated treatment with capmatinib in any line, after BM diagnosis, between May 2020 and June 2021. Data on real-worldoverall response rate (rwORR) and real-world progression-free survival (rwPFS) were descriptively analyzed. Results: 68 eligible patients were analyzed. In patients treated with first-line (1L) capmatinib (n=55), the rwORR was 90.9% systemically and 87.3% intracranially; median systemic rwPFS was 14.1months. Among radiation-naive patients on 1L capmatinib (n=20), rwORR was 85.0%, both systemically and intracranially; median systemic rwPFS was 14.1months. Conclusion: This study showed substantial systemic and intracranial effectiveness for capmatinib in real-world setting; findings were consistent for RT-naive patients. We evaluated #realworld outcomes for patients with #NSCLC with METex14 mutation and brain metastases, treated with capmatinib in clinical practice. We found substantial systemic and intracranial effectiveness with first-line capmatinib therapy.
Source: Figshare
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225998215
